Skip to Main Content

Provider Coronavirus Information

Communities around Missouri are holding community sampling COVID-19 testing events.  Please spread the word and find more information on Missouri testing sites

Information on upcoming testing events

View other Department of Health and Senior Services press releases with information about COVID-19 

Missourians do not need to live in the community where the testing is taking place.  Testing not only provides valuable health information to the individual getting the test, it will also help Missouri determine the prevalence of COVID-19 around our state.    

Access the Missouri COVID-19 Dashboard for information on the spread of COVID-19 in Missouri 

This new dashboard contains COVID-19 data that the public can review at will. 

 

Updated 10/30/2020 - COVID-19 Public Health Emergency Extended

 

In order to ensure that all of our members have needed access to care, we have increased the scope and scale of our use of telehealth services for all products for the duration of the national COVID-19 public health emergency.  These coverage expansions benefit not only members who have contracted or been exposed to the novel coronavirus, but also those members who need to seek care unrelated to COVID-19 and wish to avoid clinical settings and other public spaces.

The policies we have implemented include:

  • Continuation of zero member liability (copayments, coinsurance and/or deductible cost sharing) for care delivered via telehealth
  • Any services that can be delivered virtually will be eligible for telehealth coverage
  • Telehealth services may be delivered by providers with any connection technology to ensure patient access to care

*Please note: For Health Savings Account (HSA)-Qualified plans, IRS guidance is pending as to deductible application requirements for telehealth/telemedicine related services. 

Providers who have delivered care via telehealth should reflect it on their claim form by following standard telehealth billing protocols in their state. For further billing and coding guidance for telehealth services, we recommend following what is being published by:

We believe that these measures will help our members maintain access to quality, affordable healthcare while maintaining the CDC’s recommended distance from public spaces and groups of people. 

This guidance is in response to the current COVID-19 pandemic and may be retired at a future date.

PROVIDER BILLING GUIDANCE FOR COVID-19 TESTING, SCREENING & TREATMENT SERVICES

We are closely monitoring and following all guidance from the Centers for Medicare and Medicaid as it is released to ensure we can quickly address and support the prevention, screening, and treatment of COVID-19. The following guidance can be used to bill for services related to COVID-19 testing, screening and treatment services. This guidance is in response to the current COVID-19 pandemic and may be retired at a future date. For additional information and guidance on COVID-19 billing and coding, please visit the resource centers of the Centers for Medicare and Medicaid (CMS) and the American Medical Association (AMA).  

COVID-19 Testing Services

  • Providers performing the COVID-19 test can bill us for testing services that occurred after February 4, 2020, using the following newly created HCPCS codes:
    • HCPCS U0001 - For CDC developed tests only - 2019-nCoV Real-Time RT-PCR Diagnostic Panel.
    • HCPCS U0002 - For all other commercially available tests - 2019-nCoV Real-Time RT-PCR Diagnostic Panel.
    • CPT 87635 - Effective March 13, 2020 and issued as “the industry standard for reporting of novel coronavirus tests across the nation’s health care system.”
    • Please note:  It is not yet clear if CMS will rescind the more general HCPCS Code U0002 for non-CDC laboratory tests that the Medicare claims processing system is scheduled to begin accepting starting April 1, 2020.
  • These codes should not be used for serologic tests that detect COVID-19 antibodies.
  • All member cost share (copayment, coinsurance and/or deductible amounts) will be waived across all products for any claim billed with the new COVID-19 testing codes.
  • We have configured our systems to apply $0 member cost share liability for those claims submitted utilizing these new COVID-19 testing codes.
  • In addition to cost share, authorization requirements will be waived for any claim that is received with these specified codes.
  • Providers billing with these codes will not be limited by provider type and can be both participating and non-participating.
  • We will temporarily waive requirements that out-of-state Medicare and Medicaid providers be licensed in the state where they are providing services when they are licensed in another state.

High-Throughput Technology Testing Services

  • Providers performing high production COVID-19 diagnostic testing via high-throughput technology can bill us for testing services that occurred after February 4, 2020, using the following newly created HCPCS codes:
    • HCPCS U0003 - Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.
    • Please note: U0003 should identify tests that would otherwise be identified by CPT code 87635 but for being performed with these high throughput technologies.
    • HCPCS U0004 -2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.
    • Please note: U0004 should identify tests that would otherwise be identified by U0002 but for being performed with these high throughput technologies.
  • Neither U0003 nor U0004 should be used for tests that detect COVID-19 antibodies.
  • We have configured our systems to apply $0 member cost share liability for those claims submitted utilizing these codes to indicate high production testing.
  • Providers billing with these codes will not be limited by provider type and can be both participating and non-participating.

COVID-19 Specimen Transfers

  • For specimen transfer related claims, the following codes can be used:
    • G2023 - Spec Clct for SARS-COV-2 COVID 19 ANY SPEC SRC
    • G2024 - SP CLCT SARS-COV2 COVID19 FRM SNF/LAB ANY SPEC
    • C9803 - Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source. This is effective for services provided on or after March 1, 2020.
  • Providers billing with these codes will not be limited by provider type and can be both participating and non-participating.

COVID-19 Screening Service

  • All member cost share (copayment, coinsurance and/or deductible amounts) will be waived for COVID-19 screening visits and if billed alongside a COVID-19 testing code.
  • If no testing is performed, providers may still bill for COVID-19 screening visits for suspected contact using the following Z codes:
    • Z20.828 – Contact with a (suspected) exposure to other viral communicable diseases
    • Z03.818 – Exposure to COVID-19 and the virus is ruled out after evaluation
  • This applies to services that occurred as of February 4, 2020.
  • Providers billing with these codes will not be limited by provider type

COVID-19 Treatment Services

  • We will waive prior authorization requirements and member cost sharing for COVID-19 treatment for all members.
  • For dates of service from February 4, 2020 through March 31, 2020 providers should use the ICD-10 diagnosis code:
    • B97.29 – Confirmed Cases – other coronavirus as the cause of diseases classified elsewhere
  • For dates of service of April 1, 2020 and later, providers should use the ICD-10 diagnosis code:
    • U07.1 – 2019-nCov Confirmed by Lab Testing
  • As a reminder, only those services associated with screening and/or treatment for COVID-19 will be eligible for prior authorization and member liability waivers.  For screening or treatment not related to COVID-19 normal copayment, coinsurance, and deductibles will apply.

Reimbursement Rates for COVID-19 Services for All Provider Types

  • We are complying with the rates published by CMS for the following codes:
    • U0001 = $35.91
    • U0002 = $51.31
    • U0003 = $100.00
    • U0004 = $100.00
    • G2023 = $23.46
    • G2024 = $25.46
  • Commercial products will reimburse COVID-19 services in accordance with our negotiated commercial contract rates.
  • We will follow these CMS published rates except where state-specific Medicaid rate guidance should supersede.
  • Any additional rates will be determined by further CMS and/or state-specific guidance and communicated when available.

Due to COVID-19, we realize certain services/procedures that were previously authorized as medically necessary were not performed. Because of this, we will be extending timeframes for certain authorizations. If you were issued an approved authorization which included a service date of March 1, 2020 or after where the services were not rendered, please check our portal to see if we will be extending the authorization date span to end September 30, 2020. Our team is actively working to update our systems to show the extension dates by May 15, 2020.

Below is a listing of prior authorization categories in which will be extended:

  • Cochlear Implants & Surgery
  • Drug Testing
  • Experimental/ Investigational Procedures
  • Genetic Testing & Counseling
  • Hyperbaric Oxygen Therapy
  • Imaging
  • Elective/ Scheduled Inpatient Services
  • Mental Health Chemical Dependency Observation
  • Neuropsych Testing
  • Non-Recurring Services (specific non-par provider)
  • Office Visit
  • Outpatient Services
  • Outpatient Surgery
  • Second Opinion
  • Sleep Study
  • Surgical
  • Transplant

Healthcare Provider FAQs

  • Coronavirus disease 2019 is an emerging illness. Many details about this disease are still unknown, such as treatment options, how the virus works, and the total impact of the illness.
  • At this time, the immediate health risk from COVID-19 is considered low for the general American public who are unlikely to be exposed.
  • New information, obtained daily, will further inform the risk assessment, treatment options and next steps.
  • This is a new virus, and it is creating great concern in the community.
  • There is not a vaccine yet for this novel virus, and we do not have a specific medicine to treat it. An effective vaccine could be months or even years away- most likely 12-18 months.
  • This coronavirus is contagious – similar to the flu. Most people who become infected with the coronavirus have a mild illness or may not even have any symptoms.
  • In December 2019, there was a cluster of cases of pneumonia and respiratory diseases, first identified in the Wuhan City, Hubei Province, China.
  • Early on, many of the patients in the outbreak in Wuhan, China had some link to a large seafood and live animal market.
  • A previously unknown virus is responsible for the infections. The virus was originally named the “2019- novel coronavirus”. The virus was later renamed “SARS-CoV-2”, and the related disease is now called “coronavirus disease 2019” (or “COVID-19”).
  • Coronaviruses are a large family of viruses that are common in many different species of animals, including camels, cattle, cats, and bats. Other examples of coronaviruses include SARS-CoV and MERS- CoV.
  • SARS-CoV causes severe acute respiratory syndrome that had a global outbreak in 2003.
  • MERS-CoV causes Middle East Respiratory Syndrome, a respiratory illness that had global impact in 2012.